hcvguidelines.org - Updates/Changes March 21, 2014

[JimmyMose]

http://www.hcvguidelines.org/news/  
Home -  What’s New and Updates/Changes
Updates, Clarifications, and Corrections
Friday, March 21, 2014

Notable changes are highlighted in yellow for approximately 1 month.

Retreatment Box (Summary). Recommendations for Patients in Whom Previous PEG/RBV Treatment Has Failed

For patients with genotype 1 HCV and prior PEG/RBV failure the treatment duration of PEG/RBV in the alternate regimen SMV/PEG/RBV has been corrected to 48 weeks; for patients with genotype 4 HCV and prior PEG/RBV failure, SOF +RBV x 24 weeks was corrected to be listed as an alternative regimen and SMV/ PEG/RBV was removed as an alternative; for patients with genotype 5 or 6 HCV the incorrect listing of SOF/RBV as an alternative regimen was removed.

For patients with prior PEG/RBV/HCV protease inhibitor failure, this portion of the box was reformatted for clarity and alternative regimens by IFN eligibility have been listed.

Retreatment of Persons in Whom Prior Therapy Has Failed

1, Genotype 1. The recommended regimen for prior failures of PEG/RBV/HCV protease inhibitor regimens was added for clarity; the alternative regimen; the alternative regimen (and supporting text) for IFN ineligible patients was added.

Unique Patient Populations: HIV/HCV Coinfection Summary
Tipranavir (as described in the text) was added to the table of not allowable with SOF use.

Notice
Wednesday, March 12, 2014
NOTICE: Guidance for hepatitis C treatment is changing constantly with the advent of new therapies and other developments. A static version of this guidance, such as printout of this website material, booklet, slides, and other materials, may be outdated by the time you read this. We urge you to review this guidance on this website (www.hcvguidelines.org) for the latest recommendations.

(To navigate from news page click home tab and scroll down to Access the Full Report)

INTRODUCTION - excerpt about hcvguidelines.org
the Infectious Diseases Society of America (IDSA) and American Association for the Study of Liver Diseases (AASLD) have developed a web-based process for the rapid formulation and dissemination of evidence-based, expert-developed recommendations for hepatitis C management. The International Antiviral Society–USA (IAS–USA) provides the structure and assistance to sustain the process that represents the work of leading authorities in hepatitis C prevention, diagnosis, and treatment.

Remember it's a good idea to revisit www.hcvguidelines.org before discussing, commenting or making a treatment disision based on these guidlines.

[Upbeat]

Thanks for the info.   Good reading.  I was taken back by the new guidlines for treatment naive going only 12 weeks with Sovaldi and Simp  for all liver conditions even cirr and hcc.  With the relapse rates for Sovaldi and riba  in cirr so high it makes me wonder why they even go that way.  

http://www.hcvguidelines.org/full-report-view

[dontworry_behappy1]

Thanks for posting this information about the latest treatments.  Looks like it's updated regularly.